Data from Confirmatory Trial to be Highlighted in Oral Presentation on Sunday, June 4 WALTHAM, Mass. --(BUSINESS WIRE)--May 9, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that results from the
WALTHAM, Mass. --(BUSINESS WIRE)--May 4, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 26,000,000 shares of its common stock at a price of $12.50
WALTHAM, Mass. --(BUSINESS WIRE)--May 3, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, $200 million of shares of its
Results Show Statistically Significant Improvements in PFS, ORR, and OS Compared to Chemotherapy First Medicine to Demonstrate an Overall Survival Advantage in Platinum-Resistant Ovarian Cancer Submission of MAA in Europe and sBLA in US Anticipated in H2 2023 Conference Call to be Held at 8:00 AM
WALTHAM, Mass. --(BUSINESS WIRE)--May 1, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that in connection with the previously announced appointment of Isabel Kalofonos as ImmunoGen’s Chief
Strong Adoption of ELAHERE; Net Sales of $29.5 Million in First Full Quarter of Launch Top-Line Results from Confirmatory MIRASOL Trial Anticipated in Early May; Expected to Support Full Approval of ELAHERE in the US and Expansion into Europe Announced Non-Dilutive Financing for Up to $175 Million
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 24, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 13, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 28, 2023 to discuss its
ImmunoGen to Receive $75 Million Upon Execution of the Agreement; Eligible to Receive up to an Additional $100 Million in Near-Term Proceeds WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 6, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 3, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on March 31, 2023 , the Compensation Committee of the Company’s Board of Directors approved, in